| 翻訳と辞書 |
Synaffix
Synaffix is a preclinical-stage biotechnology company headquartered in the Netherlands that is exclusively focused on the development of technology for antibody-drug conjugates (ADCs) that are used in the treatment of cancer. ADCs utilize potent small molecule payloads, similar to those used for chemotherapy, but are intended to target only the cancer cells and spare normal tissues.
The proprietary technology of Synaffix is designed to further improve the therapeutic index of these targeted cancer therapeutics, making them better tolerated as well as more effective than the currently available treatment options. Data indicates that the resulting ADCs are not only safer but also more efficacious than an available therapy.
Synaffix was founded in 2010 based on inventions made in the field of copper-free click chemistry at the Radboud University in Nijmegen. This chemistry was combined with the use of enzymatic antibody modification in order to facilitate these targeted cancer therapeutics.
==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Synaffix」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|